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ABSTRACT 
Background: Despite growing evidence showing an association between 
Parkinson’s disease (PD) and diabetes, epidemiological studies have shown 
conflicting results.  
Aims of the study: To evaluate the association between PD and diabetes, and the 
impact of diabetes duration in this association in an elderly (≥65 years) Spanish 
population. 
Methods: Data for this cross-sectional population-based analysis were obtained from 
NEDICES study. Subjects were identified from census list. Diagnosis of PD was 
confirmed by neurological examination. Diabetes was defined by self-report, being on 
anti-diabetic medication or diagnosis on medical records. Logistic regression analysis 
adjusted by potential confounders was performed to estimate the association 
between both conditions and also after dividing patients into short-duration (<10 
years) and long-duration (≥10 years) diabetes.   
Results: 4998 subjects were included (79 PD and 4919 controls). Univariate analysis 
did not show any association between prevalence of PD and diabetes (OR 1.89, 95% 
CI 0.90 – 3.98, P = 0.09) though subgroup analysis showed a positive association in 
those with long-duration diabetes (3.27, 95% CI 1.21 – 8.85, P = 0.02).  
Conclusions: diabetes duration might be an important factor in the association 
between PD and diabetes and the risk might be limited to those with longer disease 
duration.  
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Introduction 
Increasing evidence suggests that insulin dysregulation and diabetes might 
contribute to the development of Parkinson’s disease (PD) by shared molecular 
pathways.1-3 However, this potential association remains controversial from an 
epidemiological perspective. The aim of the present study is to evaluate the 
relationship between PD and diabetes in the baseline assessment of the 
Neurological Disorders in Central Spain (NEDICES) study and evaluate the potential 
role of diabetes duration in that association. 
 
Methods 
Study population 
NEDICES study is a longitudinal population-based survey carried out between 1994-
2007 assessing community-dwelling ≥65 year-old individuals in order to estimate 
prevalence, incidence and determinants of major age-associated neurological 
conditions.4 Study protocol was approved by the local ethics institution and all 
subjects signed an informed consent at enrolment. Detailed of the study population 
and sampling methods have been published elsewhere.4-6 Briefly, subjects were 
selected by means of census lists from three different populations in central Spain in 
1994-1995. Data from this baseline cross-sectional evaluation were used for this 
study.  
 
Diagnosis of Parkinson’s disease and diabetes 
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All those subjects who screened positive on the initial validated screening 
questionnaire for parkinsonism were assessed and examined by a senior neurologist 
to confirm the diagnosis of PD.5,6 PD was defined by the presence of 2 cardinal signs 
of bradykinesia, resting tremor, rigidity and impairment of postural reflexes (or 1 
cardinal sign in those on antiparkinsonian medication) and exclusion of other causes 
of parkinsonism. Only subjects with idiopathic PD were included in the study (Table 
1).   
Diabetes was defined by self-reported diagnosis, treatment with antidiabetic 
medication (oral antidiabetics and/or insulin), or diagnosis present on medical 
records. Subjects lacking data on diabetes status were excluded from the analysis.  
 
Statistical analysis  
Variables were not normally distributed (for each Shapiro-Wilk test, P < 0.001). Chi-
squared or Fisher’s exact tests were used for categorical variables and Wilcoxon test 
for continuous or ordinal variables. All the tests were two-sided and a value of P<0.05 
was considered statistically significant. Statistical analyses were performed using the 
statistical software Stata 12 (StataCorp, TX).  
Adjusted binary logistic regression analyses were performed with PD as the 
dependent variable and diabetes (presence/absence) as the independent variable. 
To assess the association between PD and diabetes duration patients were divided 
into short-duration (<10 years) and long-duration diabetes (≥10 years) as per 
previous studies in the literature.7,8 Potential confounding was controlled by including 
demographics (gender, age); cardiovascular risk factors, previous cerebrovascular 
disease and antidiabetic treatment.  
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Results 
This study included 4,998 subjects from a total of 6,395 community-dwelling elders 
(Fig. 1). Their baseline demographic and medical characteristics are shown in Table 
2. There were 2,121 men and 2,877 women with a median age of 73 years 
(interquartile range -IQR 68 - 79). The diagnosis of prevalent PD was confirmed in 79 
subjects (1.6%). Diabetes was diagnosed in 842 subjects (16.8%) with a median 
duration of 5 years (IQR 2-13), though the information on disease duration was only 
available in 657 subjects. Main variables did not differ between both groups although 
PD subjects were slightly older (P < 0.001) and with a higher frequency of male 
gender (P = 0.03) than controls (Table 2).  
Prevalence of diabetes did not show any significant differences among PD (17.7%) 
and non-PD patients (16.8%) and the crude (unadjusted) prevalence ratio for PD 
among diabetics vs non-diabetics was 1.06 (95% CI 0.60 – 1.89, P = 0.83). Results 
of the adjusted analysis did not modify the results of this association (OR 1.89, 95% 
CI 0.90 – 3.98, P = 0.09). Covariates significantly associated to prevalent PD in this 
model were age (OR 1.05 per year, 95% CI 1.01 – 1.09, P = 0.014), and male gender 
(OR 4.06, 95% CI 2.03 – 8.12, P < 0.001) whilst current smoking showed a negative 
association to PD (OR 0.23, 95% CI 0.06 – 0.83, P = 0.024). 
Participants were divided according to diabetes duration. All patients with PD were 
included in this analysis but only 643 out of 828 diabetic controls (77.7%) had this 
information available. Groups did not differ in age or gender. Results showed a 
significant positive association between the longer diabetes duration group with 
prevalent PD after adjustment for potential confounders (reference: no diabetes; OR 
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for short-duration diabetes 1.68, 95% CI 0.70 – 4.03, P = 0.24; OR for long-duration 
diabetes 3.27, 95% CI 1.21 – 8.85, P = 0.02).  
A summary of the results of the statistical analysis with the associations between 
different groups is shown in Table 3. 
 
Discussion  
In this large population-based cross-sectional study we found no significant 
association between diabetes and PD among Spanish elderly. However our results 
suggest that diabetes duration might be an important factor on this association and 
the risk of PD might be limited to those patients with long-duration diabetes as there 
was a significant positive association between PD and those patients with long-
duration diabetes (>10years duration).  
Our study did not show a significant association between PD and diabetes in our 
sample population (OR 1.89, 95% CI 0.90 – 3.98, P = 0.09). Results of observational 
studies evaluating this association are conflicting 9,10 although in recent meta-
analysis of prospective studies diabetes was found to be a risk factor for future PD 
(RR = 1.26 [95%CI 1.03-1.55]; p <0.0001).11,12  
To our knowledge, the potential time-dependent effect of the association has been 
assessed only in two previous studies.7,8 Our results are in agreement with those of 
the Xu et al 8 showing that most of the risk is attributed to patients with disease 
duration of more than 10 years. The effect of diabetes duration is important in the 
interest of giving a pathophysiological explanation of the association, as if diabetes is 
a risk factor for PD, one will expect a higher risk among those with long history or 
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complicated diabetes. Driver et al 7 found that the increased risk for PD was highest 
among individuals with uncomplicated or short-duration diabetes (<10 years of 
duration) which was explained by the authors as a possible selection bias from 
increased medical surveillance or an underlying common biological mechanism. 
The heterogeneity of the published studies, ascertainment of PD and diabetes, and 
the effect that environment, ethnic factors and diabetes medications might have on 
the association, might explain in part the inconsistency of the results. Unfortunately 
detailed information on diabetes control and medications were not available in our 
cohort and the influence that this may have on the risk of PD could not be assessed.  
One of the main strengths of our study is the confirmation of PD diagnosis by a 
neurologist in all cases. PD cases in our study were identified from the census list in 
three different communities irrespective of their medical care with a more 
representative sample of the population with a low chance of selection bias among 
community-dwelling subjects. Results were adjusted by multiple potential 
confounders using defined and validated information obtained through face-to-face 
interviews including vascular risk factors and cases of vascular parkinsonism were 
excluded. On the other hand, our study included a relatively small number of PD 
patients (n=79) and therefore results should be interpreted with caution before 
making any firm conclusions. The cross-sectional design of the study and the lack of 
information about the temporal relation between the two diagnoses do not allow 
establishing the direction of the causal relationship between diabetes and PD. 
Apart from the observational studies discussed above, there is growing evidence 
from various areas of research suggesting a common link between diabetes and PD. 
It has been hypothesised that aberrant insulin signalling triggers a step wise 
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sequence of disruptions of regulatory pathways (including mitochondrial dysfunction, 
neuroinflammation, increased endoplasmic reticulum stress, abnormal protein 
aggregation and metabolic abnormalities) which would lead to insulin resistance and 
diabetes, and might ultimately put an individual at increased risk for PD.1-3 In addition 
to a potential increased risk for PD, diabetes has also been suggested as a modifying 
factor of the disease contributing to more severe motor symptoms requiring higher 
doses of levodopa for symptom control,13 more prominent axial motor symptoms and 
cognitive impairment.14 The possibility that PD and diabetes share dysregulated 
pathways is particularly important as further study of these mechanisms might lead to 
more effective treatments or disease modifying therapies for PD and diabetes. In this 
regard, exenatide, a synthetic agonist for the glucagon-like peptide 1 receptor 
recently granted for the treatment of diabetes, has been shown neuroprotective effect 
in an initial open label randomised controlled trial comparing 20 patients with PD 
treated with exenatide and 24 PD patients acting as controls. 15  
 
Conclusions 
The results of this population-based cross-sectional study shows no significant 
association between PD and diabetes but suggests a possible disease-duration 
dependent effect in this relationship as there is an increased prevalence of PD in 
those with long-duration diabetes after adjustment for confounding factors. Diabetes 
duration appears to reflect the effect of the cumulative toxicity of the underlying 
shared pathological mechanisms between these two diseases. Future studies should 
further explore this possibility and the effect of good diabetes control in the 
association between PD and diabetes. 
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TABLES 
Table 1. Diagnostic criteria for parkinsonism and etiologic subgroups.5,6 
Diagnosis Criteria 
Parkinsonism Presence of ≥2 cardinal signs (tremor, bradykinesia, rigidity, 
postural disturbances) in a subject not on antiparkinsonian 
medication or 
Presence of ≥1 cardinal sign in a patient on antiparkinsonian 
medication 
Drug-induced 
parkinsonism 
Treatment with dopaminergic blocking drugs within 6 months 
before symptom onset and 
Previous negative history of parkinsonian symptoms or signs and 
Improvement or resolution of the symptoms within 6 months after 
discontinuation of the offending drug a  
Vascular 
parkinsonism 
Presence of ≥2 of the following features: 
History of cerebrovascular disease with sudden onset and 
stepwise progression of parkinsonian symptoms or 
Arterial hypertension or 
Emotional incontinence and pseudobulbar palsy or 
Broad-based rigid gait or 
Widespread pyramidal signs 
Atypical 
parkinsonism 
Parkinson-plus syndromes, parkinsonism secondary to central 
nervous system infection, repeated head trauma, brain tumors or 
other conditions affecting the basal ganglia b  
Idiopathic 
Parkinson´s 
disease 
Presence of parkinsonism and enough clinical information to 
exclude vascular, drugs or atypical causes 
Unspecified 
parkinsonism 
Presence of parkinsonism with insufficient clinical information to 
reach an etiological diagnosis 
 
Footnotes. a whenever possible; b defined by routine clinical diagnosis.   
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Table 2. Demographic and clinical characteristics of participants.  
 Total 
(n=4998) 
Parkinson’s 
disease 
(n=79) 
Controls 
(n=4919) 
P Value 
Sex, female (%) 57.7 45.6 57.8 0.03 
Age, years (IQRa) 73 (68-79) 77 (72-82) 73 (68-79) <0.001 
Diabetes (%) 16.8 17.7 16.8 0.83 
Anti-diabetes therapy*    0.62 
None (%) 47.5 57.1 47.3  
Oral (%) 36.6 35.7 36.6  
Insuline (%) 15.9 7.1 16.1  
Diabetes duration, years (IQR) 5 (2-13) 8.5 (2-17) 5 (2-13) 0.52 
<10 years (%) 65.0 50.0 65.3  
≥10 years (%) 35.0 50.0 34.7  
Hypertension (%) 50.9 59.5 50.8 0.13 
Dyslipemia (%) 29.1 23.7 29.2 0.30 
Alcohol consumption    0.24 
Never (%) 46.2 55.9 46.0  
Former (%) 20.9 19.1 21.0  
Current (%) 32.9 25.0 33.1  
Smoking    0.31 
Never (%) 61.3 64.7 61.2  
Former (%) 26.9 29.4 26.9  
Current (%) 11.8 5.9 11.9  
Body mass index    0.13 
Underweight (%) 1.6 5.0 1.5  
Normal (%) 31.2 35.0 31.1  
Overweight (%) 42.6 41.7 42.6  
Obese (%) 24.6 18.3 24.7  
Stroke/TIA (%) 4.9 6.3 4.9 0.55 
DRBb drugs (%) 4.9 4.9 6.3 0.56 
 
Footnotes. *Only 657 diabetic patients included in the analysis; ainter quartile range; 
bdopamine receptor blocking drugs. 
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Table 3. Association between diabetes and Parkinson’s disease (OR and 95% CI) 
according to diabetes status and duration.  
 PD (n=79) Controls 
(n=4919) 
Unadjusted 
model 
Adjusted model 
Diabetes 
  No 65 (1.56%) 4091 (98.44%) 1.0 1.0 
  Yes 14 (1.66%) 828 (98.34%) 1.06 (0.60-1.89) 1.89 (0.90-3.98) 
Diabetes duration 
  None 65 (1.56%) 4091 (98.44%) 1.0 1.0 
  <10y 7 (1.64%) 420* (98.36%) 1.05 (0.49-2.26) 1.68 (0.70-4.03) 
  ≥10y 7 (3.04%) 223* (96.96%) 1.98 (0.91-4.28) 3.27 (1.21-8.85) 
 
Footnotes: data shown are n (%) or OR (95% CI). Adjusted model: adjusted for sex, 
age, hypertension, dyslipemia, antidiabetic treatment, alcohol consumption, smoking 
status, body mass index, presence of cerebrovascular disease and treatment with 
potential parkinsonism-inducing drugs in the logistic regression analysis. * only 643 
controls (from a total of 828) had diabetes duration information available and were 
included in this analysis. 
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FIGURES 
Fig 1. Flow-chart of the study. 
 
 
